These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22172067)

  • 1. Rational targeting of peroxisome proliferating activated receptor subtypes.
    Nevin DK; Lloyd DG; Fayne D
    Curr Med Chem; 2011; 18(36):5598-623. PubMed ID: 22172067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The next generation of PPAR drugs: do we have the tools to find them?
    Shearer BG; Billin AN
    Biochim Biophys Acta; 2007 Aug; 1771(8):1082-93. PubMed ID: 17602866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
    Menendez-Gutierrez MP; Roszer T; Ricote M
    Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective PPAR agonists for the treatment of type 2 diabetes.
    Nehlin JO; Mogensen JP; Petterson I; Jeppesen L; Fleckner J; Wulff EM; Sauerberg P
    Ann N Y Acad Sci; 2006 May; 1067():448-53. PubMed ID: 16804025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
    Patsouris D; Müller M; Kersten S
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?
    Feldman PL; Lambert MH; Henke BR
    Curr Top Med Chem; 2008; 8(9):728-49. PubMed ID: 18537685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics.
    Dixit G; Prabhu A
    Exp Mol Pathol; 2022 Feb; 124():104723. PubMed ID: 34822814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.
    Hong F; Xu P; Zhai Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.
    Peters JM; Shah YM; Gonzalez FJ
    Nat Rev Cancer; 2012 Feb; 12(3):181-95. PubMed ID: 22318237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.
    Mirza AZ; Althagafi II; Shamshad H
    Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nuclear receptors PPAR as a drug target in metabolic disorders].
    Stolarczyk M; Gutman W; Derlacz RA
    Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Pleiotropic Properties of Peroxisome Proliferator-Activated Receptors in the Heart: Focus on the Nonmetabolic Effects in Cardiac Protection.
    Barlaka E; Galatou E; Mellidis K; Ravingerova T; Lazou A
    Cardiovasc Ther; 2016 Feb; 34(1):37-48. PubMed ID: 26589375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minireview: Challenges and opportunities in development of PPAR agonists.
    Wright MB; Bortolini M; Tadayyon M; Bopst M
    Mol Endocrinol; 2014 Nov; 28(11):1756-68. PubMed ID: 25148456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for the development of new PPAR agonists in diabetes.
    Cavender MA; Nicholls SJ; Lincoff AM
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD; Plutzky J
    Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARs as therapeutic targets in cardiovascular disease.
    van Bilsen M; van Nieuwenhoven FA
    Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P; Fruchart JC; Staels B
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.
    Rosenson RS
    Am J Cardiol; 2007 Feb; 99(4A):96B-104B. PubMed ID: 17307062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.